Last updated: February 23, 2026
What is NDC 50242-0100?
NDC 50242-0100 corresponds to Vyzulta (latanoprostene bunod) ophthalmic solution, indicated for lowering intraocular pressure in glaucoma and ocular hypertension. Approved by the FDA in November 2017, it offers an alternative to traditional prostaglandin analogs.
Market Overview
Current Market Size
The global glaucoma drug market was valued at approximately USD 4.7 billion in 2022.[1] The U.S. sector accounts for roughly 60% of this, or USD 2.8-3.0 billion.
Competition Landscape
Primary competitors include:
-
Xalatan (latanoprost) — Approximate USD 215 million annual sales in the U.S.[2]
-
Lumigan (bimatoprost) — USD 180 million yearly revenue.[2]
-
Travatan Z (travoprost) — USD 90 million annually.[2]
-
Vyzulta — Launched with an initial share of 3-5%, with growth expectations.
Market Penetration Factors
-
Efficacy: Comparable or superior intraocular pressure reduction to existing PGAs.
-
Side Effects: Similar safety profiles; some reports of conjunctival hyperemia.
-
Pricing: Priced higher than generic PGAs; demand for differentiation.
-
Physician Adoption: Slow initial uptake, with a shift driven by clinical trial results and insurance coverage.
Price Projections
Current Pricing
In the U.S., the average wholesale price (AWP) for Vyzulta is approximately USD 600-700 per 2.5 mL bottle.[3] This is higher than generic latanoprost (~USD 25) but comparable to branded PGAs.
Short-Term Outlook (Next 1-2 Years)
-
Price Stability: Retail and wholesale prices are expected to remain stable due to limited generic competition.
-
Insurance Reimbursement: Managed care policies tend to reimburse at higher rates for branded drugs, supporting premium pricing.
Mid- to Long-Term Projections (3-5 Years)
-
Market Expansion: With increased adoption, price could decline marginally to USD 550-650 due to negotiations and competitive pressures.
-
Generic Entry Impact: Debates exist on the timing of generics; if generics enter in 5 years, prices could fall by 50% or more.[4]
-
Innovation and Differentiation: Potential new formulations or combo therapies could sustain or elevate pricing.
Risks to Pricing
-
Patent Litigation and Generics: Patent challenges or expirations could lead to significant price erosion.
-
Regulatory Changes: Favorable or adverse revisions in pricing policies could influence costs.
-
Market Acceptance: Slow adoption or competitive efficacy issues could reduce premium pricing.
Revenue Projections
Assuming incremental market share gains from 5% in 2022 to 15% by 2025 in the U.S., with an average price of USD 650, the revenue forecast would be:
| Year |
Estimated U.S. Market Share |
Approximate U.S. Market Revenue |
Comments |
| 2022 |
5% |
USD 150 million |
Initial launch phase |
| 2023 |
8% |
USD 250 million |
Growth phase |
| 2024 |
12% |
USD 370 million |
Increased adoption |
| 2025 |
15% |
USD 450 million |
Market saturation |
Global expansion could add an additional 10-20%, depending on regulatory approval in other regions.
Conclusion
Vyzulta's market position depends on physician preference, comparative efficacy, and pricing strategies amid competitive pressures. Price stability is expected short-term, with potential declines once generics or biosimilars emerge, likely within 5 years. Revenue growth hinges on increasing adoption and geographical expansion.
Key Takeaways
-
NDC 50242-0100 (Vyzulta) targets a growing glaucoma market with limited direct competition initially.
-
Current wholesale pricing ranges USD 600-700, with stability expected in the near term.
-
Market penetration and revenue growth rely on clinical acceptance, insurance reimbursement, and competitive dynamics.
-
Entry of generics could sharply reduce prices within 5 years, impacting revenue projections.
-
Long-term strategy should consider innovation, patent life, and regional expansion opportunities.
FAQs
1. When will generics likely enter the market for Vyzulta?
Patent exclusivity extends to 2027, with patent challenges potentially emerging before then, possibly leading to generics around 2027-2028.
2. How does Vyzulta compare clinically to other prostaglandin analogs?
Clinical trials show comparable intraocular pressure reduction to latanoprost, with some reports indicating a potential for added nitric oxide-mediated effects.
3. What are primary barriers to market growth for Vyzulta?
Physician familiarity, insurance coverage policies, and higher price points compared to generics limit early adoption.
4. What is the impact of regional approvals on Vyzulta’s global market?
Regulatory approvals outside the U.S. depend on regional health authorities. European and Asian markets are in various stages of review, influencing pricing and revenue potential accordingly.
5. How might biosimilar or alternative therapies affect Vyzulta’s market?
Introduction of biosimilars or alternative therapies with similar efficacy at lower costs could erode market share and reduce prices.
References
[1] Grand View Research. (2022). Glaucoma Drugs Market Size, Share & Trends.
[2] IQVIA. (2022). U.S. Prescription Market Data.
[3] GoodRx. (2022). Vyzulta pricing information.
[4] EvaluatePharma. (2022). Patent expiry analysis in ophthalmology drugs.
